Intuitive Surgical shares suffered a steep decline Friday after investors focused on the robotic-surgery company’s unchanged procedure-growth outlook rather than its stronger-than-expected second-quarter financial results.
The stock dropped approximately 14%, falling to its lowest level since early 2024. Intuitive Surgical became the worst-performing stock in both the S&P 500 and Nasdaq 100 during the session. The decline also left shares nearly 40% below where they began 2026.
The selloff came even though Intuitive Surgical exceeded Wall Street’s quarterly expectations. The company reported adjusted earnings of $2.80 per share, while revenue increased 19% from the previous year to $2.89 billion.
Intuitive Surgical’s revenue growth was supported by increasing procedure volumes, additional leasing revenue and the continued expansion of its installed base of da Vinci and Ion systems. Revenue from instruments and accessories rose 18% to $1.73 billion, while systems revenue increased to $685 million from $575 million one year earlier.
Worldwide procedures involving the company’s da Vinci and Ion platforms increased approximately 16% from the second quarter of 2025. Da Vinci procedures rose about 15%, while procedures involving the Ion system increased roughly 36%. Intuitive also placed 468 da Vinci systems during the quarter, compared with 395 during the same period last year.
However, investors were disappointed that management did not increase its full-year forecast for worldwide da Vinci procedure growth. Intuitive continued to project growth of approximately 13.5% to 15.5% and said it expected the final result to be closer to the midpoint of that range.
That outlook suggested procedure growth could continue slowing. Da Vinci procedure volume increased 15% during the second quarter after growing 17% during the first three months of the year. Investors had apparently expected the company’s strong earnings and revenue performance to be accompanied by an increased annual forecast.
William Blair analysts said Intuitive Surgical’s premium valuation created elevated expectations and that simply repeating the existing procedure forecast was not enough to satisfy investors looking for another quarter of stronger results followed by raised guidance.
William Blair maintained its outperform rating on Intuitive Surgical but identified several risks facing the company. Those included increasing competition in China and weaker procedure volumes connected to declining enrollment in Affordable Care Act health plans.
Intuitive Surgical has said changes in patient insurance coverage and premium costs may be affecting when some people seek treatment, particularly for procedures that can be postponed. The company described the expiration of enhanced Affordable Care Act subsidies as having a modest negative effect on second-quarter procedure growth.
Despite the market’s negative reaction, Wall Street analysts continued to see substantial potential upside in the stock. The average analyst price target tracked by Visible Alpha was $509, representing nearly 50% upside from Intuitive Surgical’s Friday closing level.
The sharp decline therefore reflected concerns about the company’s future growth rate and elevated valuation rather than weak quarterly earnings. Intuitive Surgical continued to expand revenue, earnings, procedure volume and system placements, but investors had been expecting management to provide a stronger signal that those trends would accelerate during the remainder of the year.
Source: Investopedia
